Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003

Tsi S. Huang, Calvin M. Kunin, S. S J Lee, Yao Shen Chen, Hui Z. Tu, Yung Ching Liu

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Objectives: Fluoroquinolones are being used more frequently for the treatment of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis complex (MTB). This study was designed to determine the frequency of the emergence of fluoroquinolone-resistant strains in Taiwan and to assess whether this might be due to use of fluoroquinolones for treatment of patients with MDR or because of increased use of fluoroquinolones in the community for treatment of other infections. We also sought to determine whether there might be clonal spread of fluoroquinolone resistance. Methods: A total of 3497 clinical isolates of M. tuberculosis complex were obtained during 1995-2003, of which 141 were selected. They consisted of 62 isolates fully susceptible to four first-line drugs, 33 isolates resistant to rifampicin and isoniazid (MDR), and 46 isolates with a variety of any drug resistant patterns other than MDR (combination group). The MICs were determined for ciprofloxacin, ofloxacin and levofloxacin. Results: An increase in the MIC90 and rates of resistance to ciprofloxacin, ofloxacin and levofloxacin were noted only in the MDR group. The rates were higher among strains isolated between 1998-2003 compared with those obtained between 1995-1997 (rate of resistance, 20% versus 7.7%; MIC ≥ 4 mg/L versus 1-2 mg/L). Among the 10 fluoroquinolone-resistant isolates, five (50%) possessed mutations other than S95T in the gyrA gene. No gyrB mutation was found in any of the clinical isolates. Conclusions: These findings suggest that fluoroquinolone resistance is the result of treatment of patients with MDR strains rather than from use in the general community in Taiwan. The emergence of fluoroquinolone resistance among MDR strains reinforces the need for routine fluoroquinolone susceptibility testing whenever these drugs might be used.

Original languageEnglish
Pages (from-to)1058-1062
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Volume56
Issue number6
DOIs
Publication statusPublished - Dec 2005
Externally publishedYes

Fingerprint

Fluoroquinolones
Mycobacterium tuberculosis
Levofloxacin
Ofloxacin
Ciprofloxacin
Taiwan
Pharmaceutical Preparations
Mutation
Isoniazid
Multiple Drug Resistance
Therapeutics
Rifampin
Infection

Keywords

  • Fluoroquinolone resistance
  • TB
  • Treatment

ASJC Scopus subject areas

  • Microbiology
  • Pharmacology

Cite this

Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre : 1995-2003. / Huang, Tsi S.; Kunin, Calvin M.; Lee, S. S J; Chen, Yao Shen; Tu, Hui Z.; Liu, Yung Ching.

In: Journal of Antimicrobial Chemotherapy, Vol. 56, No. 6, 12.2005, p. 1058-1062.

Research output: Contribution to journalArticle

Huang, Tsi S. ; Kunin, Calvin M. ; Lee, S. S J ; Chen, Yao Shen ; Tu, Hui Z. ; Liu, Yung Ching. / Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre : 1995-2003. In: Journal of Antimicrobial Chemotherapy. 2005 ; Vol. 56, No. 6. pp. 1058-1062.
@article{f2d7daed0b034d758c08b42504d2e584,
title = "Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003",
abstract = "Objectives: Fluoroquinolones are being used more frequently for the treatment of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis complex (MTB). This study was designed to determine the frequency of the emergence of fluoroquinolone-resistant strains in Taiwan and to assess whether this might be due to use of fluoroquinolones for treatment of patients with MDR or because of increased use of fluoroquinolones in the community for treatment of other infections. We also sought to determine whether there might be clonal spread of fluoroquinolone resistance. Methods: A total of 3497 clinical isolates of M. tuberculosis complex were obtained during 1995-2003, of which 141 were selected. They consisted of 62 isolates fully susceptible to four first-line drugs, 33 isolates resistant to rifampicin and isoniazid (MDR), and 46 isolates with a variety of any drug resistant patterns other than MDR (combination group). The MICs were determined for ciprofloxacin, ofloxacin and levofloxacin. Results: An increase in the MIC90 and rates of resistance to ciprofloxacin, ofloxacin and levofloxacin were noted only in the MDR group. The rates were higher among strains isolated between 1998-2003 compared with those obtained between 1995-1997 (rate of resistance, 20{\%} versus 7.7{\%}; MIC ≥ 4 mg/L versus 1-2 mg/L). Among the 10 fluoroquinolone-resistant isolates, five (50{\%}) possessed mutations other than S95T in the gyrA gene. No gyrB mutation was found in any of the clinical isolates. Conclusions: These findings suggest that fluoroquinolone resistance is the result of treatment of patients with MDR strains rather than from use in the general community in Taiwan. The emergence of fluoroquinolone resistance among MDR strains reinforces the need for routine fluoroquinolone susceptibility testing whenever these drugs might be used.",
keywords = "Fluoroquinolone resistance, TB, Treatment",
author = "Huang, {Tsi S.} and Kunin, {Calvin M.} and Lee, {S. S J} and Chen, {Yao Shen} and Tu, {Hui Z.} and Liu, {Yung Ching}",
year = "2005",
month = "12",
doi = "10.1093/jac/dki353",
language = "English",
volume = "56",
pages = "1058--1062",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre

T2 - 1995-2003

AU - Huang, Tsi S.

AU - Kunin, Calvin M.

AU - Lee, S. S J

AU - Chen, Yao Shen

AU - Tu, Hui Z.

AU - Liu, Yung Ching

PY - 2005/12

Y1 - 2005/12

N2 - Objectives: Fluoroquinolones are being used more frequently for the treatment of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis complex (MTB). This study was designed to determine the frequency of the emergence of fluoroquinolone-resistant strains in Taiwan and to assess whether this might be due to use of fluoroquinolones for treatment of patients with MDR or because of increased use of fluoroquinolones in the community for treatment of other infections. We also sought to determine whether there might be clonal spread of fluoroquinolone resistance. Methods: A total of 3497 clinical isolates of M. tuberculosis complex were obtained during 1995-2003, of which 141 were selected. They consisted of 62 isolates fully susceptible to four first-line drugs, 33 isolates resistant to rifampicin and isoniazid (MDR), and 46 isolates with a variety of any drug resistant patterns other than MDR (combination group). The MICs were determined for ciprofloxacin, ofloxacin and levofloxacin. Results: An increase in the MIC90 and rates of resistance to ciprofloxacin, ofloxacin and levofloxacin were noted only in the MDR group. The rates were higher among strains isolated between 1998-2003 compared with those obtained between 1995-1997 (rate of resistance, 20% versus 7.7%; MIC ≥ 4 mg/L versus 1-2 mg/L). Among the 10 fluoroquinolone-resistant isolates, five (50%) possessed mutations other than S95T in the gyrA gene. No gyrB mutation was found in any of the clinical isolates. Conclusions: These findings suggest that fluoroquinolone resistance is the result of treatment of patients with MDR strains rather than from use in the general community in Taiwan. The emergence of fluoroquinolone resistance among MDR strains reinforces the need for routine fluoroquinolone susceptibility testing whenever these drugs might be used.

AB - Objectives: Fluoroquinolones are being used more frequently for the treatment of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis complex (MTB). This study was designed to determine the frequency of the emergence of fluoroquinolone-resistant strains in Taiwan and to assess whether this might be due to use of fluoroquinolones for treatment of patients with MDR or because of increased use of fluoroquinolones in the community for treatment of other infections. We also sought to determine whether there might be clonal spread of fluoroquinolone resistance. Methods: A total of 3497 clinical isolates of M. tuberculosis complex were obtained during 1995-2003, of which 141 were selected. They consisted of 62 isolates fully susceptible to four first-line drugs, 33 isolates resistant to rifampicin and isoniazid (MDR), and 46 isolates with a variety of any drug resistant patterns other than MDR (combination group). The MICs were determined for ciprofloxacin, ofloxacin and levofloxacin. Results: An increase in the MIC90 and rates of resistance to ciprofloxacin, ofloxacin and levofloxacin were noted only in the MDR group. The rates were higher among strains isolated between 1998-2003 compared with those obtained between 1995-1997 (rate of resistance, 20% versus 7.7%; MIC ≥ 4 mg/L versus 1-2 mg/L). Among the 10 fluoroquinolone-resistant isolates, five (50%) possessed mutations other than S95T in the gyrA gene. No gyrB mutation was found in any of the clinical isolates. Conclusions: These findings suggest that fluoroquinolone resistance is the result of treatment of patients with MDR strains rather than from use in the general community in Taiwan. The emergence of fluoroquinolone resistance among MDR strains reinforces the need for routine fluoroquinolone susceptibility testing whenever these drugs might be used.

KW - Fluoroquinolone resistance

KW - TB

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=29444440874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29444440874&partnerID=8YFLogxK

U2 - 10.1093/jac/dki353

DO - 10.1093/jac/dki353

M3 - Article

C2 - 16204341

AN - SCOPUS:29444440874

VL - 56

SP - 1058

EP - 1062

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 6

ER -